IME (IME) News
Follow IME (IME) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
IME says AI agents are live; EBITDA up 4x and raises growth targets
ImExHS says AI agents are now live in hospitals, citing improved EBITDA and stable recurring revenue. It targets 8—16% revenue growth and 48—66% EBITDA growth, with Colombia collections a key risk.
EARNINGS | Sep 02, 2026, 02:12 AM UTC
L
IME reports 17% revenue growth, ARR $36.8m; EBITDA jumps 311%
ImExHS says revenue rose 17% year-over-year and ARR reached $36.8m. It also reports underlying EBITDA up 311% and guidance for FY26 calls for continued growth in revenue and earnings.
EARNINGS | Sep 02, 2026, 12:23 AM UTC
L
ImexHS cut to Hold from Morgans spec buy
TradingView News reports ImexHS was cut to Hold from a Morgans speculative buy for IME.AU.
EQUITY | Aug 31, 2026, 11:34 PM UTC
L
ImexHS target price cut 26% to A$0.37 by Morgans
Morgans cut ImexHS’s target price by 26% to A$0.37 per share for IME.AU.
EQUITY | Aug 31, 2026, 11:34 PM UTC
M
IME reports revenue up 17% to $16m and EBITDA $1.3m
IME revenue rose 17% to $16m, ARR increased 12%, and EBITDA rose to $1.3m.
EQUITY | Aug 28, 2026, 01:09 AM UTC
L
IME reports strong revenue growth and return to profit
IME sees strong revenue growth and a return to profit, but liquidity risks and going-concern uncertainty persist.
EARNINGS | Aug 27, 2026, 11:56 PM UTC